Jennifer A. Huntington

发表

Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

J. Long, Myra W. Popejoy, Jennifer A. Huntington, 2017, BMC Infectious Diseases.

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

D. Nicolau, A. Xiao, Jennifer A. Huntington, 2015, Journal of clinical pharmacology.

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

D. Paterson, K. Kaye, E. Hershberger, 2017, The Journal of antimicrobial chemotherapy.

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

R. Wunderink, M. Kollef, J. Timsit, 2022, Critical Care.

Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial

M. Castanheira, M. Motyl, Elizabeth G. Rhee, 2020, Antimicrobial Agents and Chemotherapy.

Daptomycin Therapy for Osteomyelitis: A Retrospective Study

Jason C. Gallagher, E. Berbari, M. Yoon, 2012, BMC Infectious Diseases.

Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study

Elizabeth G. Rhee, A. Adedoyin, E. Hershberger, 2018, Clinical pharmacology in drug development.

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

K. Rodvold, M. Gotfried, G. Chandorkar, 2012, The Journal of antimicrobial chemotherapy.

Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

R. Wunderink, M. Kollef, J. Timsit, 2019, The Lancet. Infectious diseases.

Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.

M. Castanheira, D. Paterson, M. Bassetti, 2022, The Journal of antimicrobial chemotherapy.

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

R. Wunderink, M. Kollef, J. Timsit, 2021, Critical Care.

PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease

R. Kullar, A. Xiao, L. Caro, 2016, Infectious Diseases and Therapy.

Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase 3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).

M. Castanheira, M. Motyl, Elizabeth G. Rhee, 2021, International journal of antimicrobial agents.

1044Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial

E. Goldstein, G. Sakoulas, M. Yoon, 2014, The Journal of antimicrobial chemotherapy.

Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.

J. Long, A. Xiao, L. Caro, 2018, International journal of antimicrobial agents.

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

M. Kollef, A. Shorr, Elizabeth G. Rhee, 2021, Critical Care.

Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection

Elizabeth G. Rhee, J. Newland, Julia D. Lonchar, 2023, The Pediatric infectious disease journal.

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial

Elizabeth G. Rhee, E. Roilides, J. Bradley, 2023, The Pediatric infectious disease journal.

Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)

Elizabeth G. Rhee, Hwa-ping Feng, E. Jensen, 2020, Antimicrobial Agents and Chemotherapy.

1154. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-abdominal Infection: A Phase 2, Randomized Clinical Trial

Elizabeth G. Rhee, J. Newland, Julia D. Lonchar, 2021, Open Forum Infectious Diseases.

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

R. Wunderink, M. Kollef, J. Timsit, 2023, Annals of Intensive Care.